Literature DB >> 21565412

Connectomics of orexin-producing neurons: interface of systems of emotion, energy homeostasis and arousal.

Takeshi Sakurai1, Michihiro Mieda.   

Abstract

Avoiding danger and finding food, which are life-sustaining activities that are regulated by emotion, reward and energy balance, require proper wakefulness. The orexin system controls sleep and wakefulness through interactions with systems that regulate emotion, reward and energy homeostasis. Recent findings have brought about the possibility of novel therapies targeting the orexin system for sleep disorders, including insomnia and narcolepsy-cataplexy, as well as other pathological conditions such as obesity and drug addiction [1]. In this review, we will discuss the current understanding of the integrative physiology and clinical perspectives of the orexin system. We will briefly review signaling through orexin A and B receptors and discuss the role of orexins in the pathophysiology of narcolepsy. We will also examine connections between orexin neurons and other brain areas involved in feeding behavior, reward and emotion. Finally, we will consider the therapeutic potential of drugs that target orexin receptors.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21565412     DOI: 10.1016/j.tips.2011.03.007

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  68 in total

1.  Intramolecular fluorescence resonance energy transfer (FRET) sensors of the orexin OX1 and OX2 receptors identify slow kinetics of agonist activation.

Authors:  Tian-Rui Xu; Richard J Ward; John D Pediani; Graeme Milligan
Journal:  J Biol Chem       Date:  2012-03-02       Impact factor: 5.157

Review 2.  Role of orexin in the pathophysiology of depression: potential for pharmacological intervention.

Authors:  Mathieu Nollet; Samuel Leman
Journal:  CNS Drugs       Date:  2013-06       Impact factor: 5.749

3.  Translational profiling of hypocretin neurons identifies candidate molecules for sleep regulation.

Authors:  Jasbir Dalal; Jee Hoon Roh; Susan E Maloney; Afua Akuffo; Samir Shah; Han Yuan; Brie Wamsley; Wendell B Jones; Cristina de Guzman Strong; Paul A Gray; David M Holtzman; Nathaniel Heintz; Joseph D Dougherty
Journal:  Genes Dev       Date:  2013-02-21       Impact factor: 11.361

Review 4.  Peptide neuromodulation in invertebrate model systems.

Authors:  Paul H Taghert; Michael N Nitabach
Journal:  Neuron       Date:  2012-10-04       Impact factor: 17.173

Review 5.  Suvorexant in insomnia: efficacy, safety and place in therapy.

Authors:  Danielle N Rhyne; Sarah L Anderson
Journal:  Ther Adv Drug Saf       Date:  2015-10

6.  The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

Review 7.  The Deakin/Graeff hypothesis: focus on serotonergic inhibition of panic.

Authors:  Evan D Paul; Philip L Johnson; Anantha Shekhar; Christopher A Lowry
Journal:  Neurosci Biobehav Rev       Date:  2014-03-21       Impact factor: 8.989

8.  Association of Dietary Variety and Appetite with Sleep Quality in Urban-Dwelling Older Japanese Adults.

Authors:  K Yamamoto; K Motokawa; T Yoshizaki; T Yano; H Hirano; Y Ohara; M Shirobe; H Inagaki; S Awata; S Shinkai; Y Watanabe
Journal:  J Nutr Health Aging       Date:  2020       Impact factor: 4.075

9.  GABAB agonism promotes sleep and reduces cataplexy in murine narcolepsy.

Authors:  Sarah Wurts Black; Stephen R Morairty; Tsui-Ming Chen; Andrew K Leung; Jonathan P Wisor; Akihiro Yamanaka; Thomas S Kilduff
Journal:  J Neurosci       Date:  2014-05-07       Impact factor: 6.167

10.  Almorexant promotes sleep and exacerbates cataplexy in a murine model of narcolepsy.

Authors:  Sarah Wurts Black; Stephen R Morairty; Simon P Fisher; Tsui-Ming Chen; Deepti R Warrier; Thomas S Kilduff
Journal:  Sleep       Date:  2013-03-01       Impact factor: 5.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.